Elekta (EKTA-B.ST) announces that All India Institute of Medical Science (AIIMS) will acquire seven Versa HD linear accelerators and six microSelectron brachytherapy systems. The investment supports AIIMS's current phase of sustained expansion, which represents India's largest public investment in health sector.
The agreement also includes Elekta's Monaco treatment planning system and MOSAIQ radiation oncology information system, as well as service for both hardware and software.
Charles Schanen, Senior Vice President, Region Asia Pacific says, "We are very happy to support AIIMS as it introduces sophisticated cancer treatment technology to treat this widespread disease."
"Versa HD, the most advanced linear accelerator, will be an excellent asset as it is capable of delivering stereotactic body radiotherapy (SBRT) and radiosurgery (SRS). Cervical cancer is ranked as the most frequent type for women in India. Brachytherapy (internal radiotherapy) is one of the most common methods used to treat cancer of the cervix and our microSelectron remote afterloading platform should benefit thousands of Indian women suffering from this cancer."
Every year approximately 4,000 new patients consult AIIMS to receive various radiotherapy treatments. Elekta's agreement with AIIMS covers seven sites across India.